Discussion about this post

User's avatar
Kevin Curran CFA's avatar

Thanks for sharing your work, which I found to be well written and high quality. Although American now, I'm from the UK originally and went to college there - I'd say that overall, the risk to the UK's international students is modest at worst. They just depend too much on the revenues those students bring, plus the UK is just way more diverse and has been for years and those students fit in well - contrast with the concentration of Punjabi Indians using student visas as a backdoor to PR in Canada. If there's one thing I'd love to see in the report it's just what your 2026 numbers look like as I have my own guesses. What jumps out in my numbers, even assuming continued pressure in the three troubled markets, is that the revenue mix has those three down to 15% or so in 2026 due to full year of Sertify and just good growth elsewhere and of course reduced revs from those markets over the last 2 years. It's just hard for these tails to keep wagging the overall Flywire dog. Hopefully the focus can shift to SFS grow out and also it would be great if they company is able to offer up some nuggets in terms of when and by how much they can augment the Sertify related revenues as I suspect they have a good sense by now and those numbers could be way more impactful on the positive side than the US may look on the negative. One potential acquirer to ponder as well - SOFI. They just did a $1.5bn common raise, and they service students of course so FLYW could be a good source of leads globally. Doubt FLYW sells themselves as their stock could 3x in a year quite easily (PAY went up 5x from the 2023 lows as their narrative changed for the better so it happens). Cheers

Kevin Curran CFA's avatar

I was intrigued by your comments regarding the possible divestiture of the healthcare unit - so far the results from the operational review have been more run of the mill type stuff but such a divestiture could be stock price enhancing given how undervalued it is. Healthcare is the most standalone unit that doesn’t benefit from Flywire's global payment platform. The core of the unit was bought in 2020, coincident with a $120m funding round although not sure what they actually paid. As we now know, within the last year they have regained momentum with the business about to expand around 30-35% starting in late 2025 with the onboarding of the prestigious and large ("8 figure") NYC based hospital system. That reputation enhancing contract win is helping them develop the pipeline and it makes this unit very attractive as it could lead to a few years of good growth. I peg 2026 unit revs at $41m, and it’s a high quality recurring revenue stream. One healthtech payments firm I see is Waystar and it trades at 6.2x ev/sales on 2026 per consensus extracted from Koyfin. Stock seems like it's a low double digit grower so seems like a decent comp although I'm open to debate on this as I'm not familiar with it. That would peg the value of Flywire's unit at about $250m. Along with their $171m current net cash at 1Q25 plus maybe $100m NTM cash generation that's a lot of buyback firepower for a $1.3bn mkt cap. 40% of market cap to be precise. The whole firm trades at 1.6x ev/sales right now per Koyfin so offloading this asset (only 6% or so or 2026 revenues) at 6.2x, or even 4.2x) would go some way to offsetting the poor sentiment over the Sertify price paid (albeit the bulls on the stock will argue that like WPM in the UK, Sertify is a saas asset that's ripe for rapid payments monetization - and geographic expansion in this case as well). Crazy that this market is fixated on maybe a 2% risk to revenues from US cross border education when there's so much upside to numbers from other sources. Hopefully they stop taking the BS from the market and spell things out that these dummies can understand.

14 more comments...

No posts

Ready for more?